Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A

Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A

SSZSE:300254
7.05
CNY
-0.19
(-2.62%)
0.15EPS
100.39P/E
2.36BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 2.36B, placing it among publicly traded companies globally. Its enterprise value stands at 2.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.36B
Enterprise Value2.80B

Share Statistics

As of September 30, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A has 257.21M shares outstanding.

Shares Outstanding257.21M

Valuation Ratios

As of September 30, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 100.39. The price-to-sales ratio is 2.81, and the price-to-book ratio stands at 4.72.

PE Ratio100.39
PS Ratio2.81
PB Ratio4.72
P/TBV Ratio-210.78

Enterprise Valuation

As of September 30, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A trades at an EV/EBITDA multiple of 62.61 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 62.61 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.80B versus a market cap of 2.36B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.51
EV / EBITDA62.61
EV / EBIT62.61

Financial Position

As of September 30, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 1.03, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 91.45, indicating elevated leverage, while an interest coverage ratio of 2.00 demonstrates limited ability to service its debt obligations.

Current Ratio1.03
Quick Ratio0.25
Debt / Equity91.45
Debt / EBITDA11.46
Interest Coverage2.00

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 686,377.77 in revenue per employee across its workforce of 1,162.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee686,377.77
Employee Count1,162.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A recorded 21.57M in income tax expense. That works out to an effective tax rate of 36.87, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 58.52M, leaving 22.33M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax21.57M
Effective Tax Rate36.87

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A's stock has declined approximately 37.99% over the past 52 weeks. The 50-day moving average sits at 8.34, while the 200-day moving average is 10.01.

52-Week Price Change-37.99%
50-Day Moving Average8.34
200-Day Moving Average10.01

Income Statement

CNY

Over the twelve months ended September 30, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A generated 797.57M in revenue and converted that into 22.33M in net income, yielding earnings per share of 0.15. EBITDA reached 44.76M, while operating income came in at 86.10M.

Revenue797.57M
Gross Profit519.24M
Operating Income86.10M
Pretax Income58.52M
Net Income22.33M
EBITDA44.76M
EBIT44.76M
Earnings Per Share (EPS)0.15

Balance Sheet

CNY

As of September 30, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A holds 134.03M in cash and equivalents against 512.77M in total debt, resulting in a net debt position of 256.59M. Total book value stands at 500.92M, with working capital of 14.25M providing operational flexibility.

Cash & Cash Equivalents134.03M
Total Debt512.77M
Net Debt256.59M
Equity (Book Value)500.92M
Book Value Per Share1.95
Working Capital14.25M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-30.40M

Margins

Over the twelve months ended September 30, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A posted a gross margin of 65.10, reflecting its pricing power and cost economics. The operating margin of 10.80 and net profit margin of 2.80 provide insight into operational efficiency.

Gross Margin65.10
Operating Margin10.80
Pretax Margin7.34
Profit Margin2.80
EBITDA Margin5.61

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A paid dividends of 0.07 per share. The dividend payout ratio of 33.46 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 4.49, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A shareholders.

Dividend Per Share0.07
Payout Ratio33.46
Shareholder Yield4.49

Stock Splits

Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on July 8, 2016 with a 5:6 split ratio.

Last Split Date7/8/2016
Split Ratio5:6

Scores

As of September 30, 2026, Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A has an Altman Z-Score of 2.17, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.17